Stephen Hart obtained his PhD from the University of Cape Town then undertook a postdoc at St. Mary’s, London for three years before joining the Institute of Child Health (ICH) as a postdoc then Lecturer. He was promoted to professor in 2012 and is currently Deputy Head of the Genetics and Genomic Medicines programme at ICH. He has worked in the field of genetic therapies for more than 20 years with more than 100 publications to his name. His current research activities include the development of gene therapy, including gene editing strategies, for the treatment of cystic fibrosis, primary ciliary dyskinesias and neuroblastoma. His group have developed novel synthetic nanoparticles for the delivery of nucleic acid therapeutics including siRNA, messenger RNA and CRISPR/Cas9 formulations. This work has also led to being named inventor on nine patents concerning nanoparticle delivery formulations. He is the lead investigator on a Strategic Research Centre grant funded by the Cystic Fibrosis Trust, developing CRISPR gene editing therapies for cystic fibrosis. In 2017 Stephen was elected to the board of directors of the American Society of Gene and Cell Therapy. He is a Senior Editor for the journal Annals of Human Genetics, a member of the editorial board for the journal Genes and an assistant editor for Nature Scientific Reports. In 2011 he raised the financial investment to become the scientific founder of Nanogenic Solutions Ltd, a UCL spin-out company, commercialising nanoparticle delivery formulations for genetic therapies.